Zealand Pharma: Helsinn returns elsiglutide's rights.
(CercleFinance.com) - Danish biotechnology company Zealand Pharma said on Monday that Switzerland's Helsinn had returned rights on elsiglutidean, an experimental treatment of chemotherapy-induced diarrhea.
Elsiglutide is a novel GLP-2 peptide analogue invented by Zealand that was licensed globally to Helsinn in 2008 for use in cancer-supportive care.
The licence agreement between the two companies has now been concluded.
Zealand has said that it plans to pursue the drug's development in line with its strategy of developing fully-owned programs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Elsiglutide is a novel GLP-2 peptide analogue invented by Zealand that was licensed globally to Helsinn in 2008 for use in cancer-supportive care.
The licence agreement between the two companies has now been concluded.
Zealand has said that it plans to pursue the drug's development in line with its strategy of developing fully-owned programs.
Copyright (c) 2017 CercleFinance.com. All rights reserved.